Of note, GABAergic deficits have been observed in schizophrenia. Therefore, any reduction of GABA release by cannabinoids in the presence of a preexisting GABA deficit, as might be the case in schizophrenia, may explain why schizophrenia patients show heightened sensitivity to the effects of cannabinoids.